May is a busy but invigorating season for the TCTMD team—in-person connections abound and the stream of data never stops. The ...

A meta-analysis suggests adverse events are often falsely attributed to BP-lowering drugs, leaving patients undertreated.

Durability questions remain, but Myval appears comparable to contemporary devices on the market, says Patrick Serruys.

The curves for TVF separated early and remained parallel in the complex cases, giving an advantage to the DCB group at 1 year ...

Women continue to be underdiagnosed and undertreated for cardiovascular disease around the world—to overcome this gap, a new joint statement from the European Society of Cardiology (ESC) and other ...

After the sponsor halted the trial, despite the DSMB’s advice to continue, investigators aimed to salvage the scientific value.

This month: questionable value of management consultants, BP across the lifespan, patient frailty perspectives in HF, and more.

Top-line results from the phase III trial show average weight losses of 19% to 28.3% by 80 weeks depending on dose.

The Bioadaptor coronary implant (Elixir Medical) continues to outperform contemporary drug-eluting stent technology over ...

Heart failure (HF) patients who have reduced or mildly reduced ejection fraction derive better outcomes when low-dose digoxin ...

There are still some kinks to be ironed out, including risks of hemolysis and valve thrombosis, to put things on par with ...

For stabilized patients undergoing complex PCI, left ventricular unloading with an Impella CP microaxial flow pump ...